206 related articles for article (PubMed ID: 29328401)
21. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3.
Hu H; Wang Y; Ding X; He Y; Lu Z; Wu P; Tian L; Yuan H; Liu D; Shi G; Xia T; Yin J; Cai B; Miao Y; Jiang K
Mol Cancer; 2018 Jan; 17(1):18. PubMed ID: 29386037
[TBL] [Abstract][Full Text] [Related]
22. Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Jin H; Zhao Y; Zhang S; Yang J; Zhang X; Ma S
Mol Med Rep; 2018 May; 17(5):7274-7280. PubMed ID: 29568909
[TBL] [Abstract][Full Text] [Related]
23. The Long Noncoding RNA HOST2 Promotes Gemcitabine Resistance in Human Pancreatic Cancer Cells.
An N; Cheng D
Pathol Oncol Res; 2020 Jan; 26(1):425-431. PubMed ID: 30406400
[TBL] [Abstract][Full Text] [Related]
24. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
Yang F; Li X; Zhang L; Cheng L; Li X
J Pharmacol Sci; 2018 Jun; 137(2):116-121. PubMed ID: 29960845
[TBL] [Abstract][Full Text] [Related]
25. Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer.
Yamaguchi J; Kokuryo T; Yokoyama Y; Oishi S; Sunagawa M; Mizuno T; Onoe S; Watanabe N; Ogura A; Ebata T
Cancer Med; 2024 Jun; 13(11):e7395. PubMed ID: 38872370
[TBL] [Abstract][Full Text] [Related]
26. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Okada Y; Takahashi N; Takayama T; Goel A
Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
[TBL] [Abstract][Full Text] [Related]
27. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
28. lncRNA MEG3 inhibits pituitary tumor development by participating in cell proliferation, apoptosis and EMT processes.
Wang X; Li X; Wang Z
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649837
[TBL] [Abstract][Full Text] [Related]
29. DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.
Guo Q; Qin W
J Cell Mol Med; 2015 Dec; 19(12):2832-41. PubMed ID: 26395974
[TBL] [Abstract][Full Text] [Related]
30. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Zhang X; Zhao P; Wang C; Xin B
Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
[TBL] [Abstract][Full Text] [Related]
31. CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Xu P; Yao J; He J; Zhao L; Wang X; Li Z; Qian J
Oncotarget; 2016 Mar; 7(12):14831-40. PubMed ID: 26894380
[TBL] [Abstract][Full Text] [Related]
32. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
[TBL] [Abstract][Full Text] [Related]
33. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
34. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis.
Li L; Shang J; Zhang Y; Liu S; Peng Y; Zhou Z; Pan H; Wang X; Chen L; Zhao Q
Oncol Rep; 2017 Sep; 38(3):1383-1392. PubMed ID: 28731151
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression.
Han Q; Li J; Xiong J; Song Z
J Exp Clin Cancer Res; 2020 Aug; 39(1):151. PubMed ID: 32771045
[TBL] [Abstract][Full Text] [Related]
36. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
[TBL] [Abstract][Full Text] [Related]
37. ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.
Gharibi A; La Kim S; Molnar J; Brambilla D; Adamian Y; Hoover M; Hong J; Lin J; Wolfenden L; Kelber JA
Sci Rep; 2017 Aug; 7(1):10060. PubMed ID: 28855593
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.
Moriyama T; Ohuchida K; Mizumoto K; Yu J; Sato N; Nabae T; Takahata S; Toma H; Nagai E; Tanaka M
Mol Cancer Ther; 2009 May; 8(5):1067-74. PubMed ID: 19435867
[TBL] [Abstract][Full Text] [Related]
39. Long noncoding RNA MEG3 decreases the growth of head and neck squamous cell carcinoma by regulating the expression of miR-421 and E-cadherin.
Ji Y; Feng G; Hou Y; Yu Y; Wang R; Yuan H
Cancer Med; 2020 Jun; 9(11):3954-3963. PubMed ID: 32277605
[TBL] [Abstract][Full Text] [Related]
40. The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
Sun Y; Wang P; Yang W; Shan Y; Zhang Q; Wu H
Cancer Biol Ther; 2019; 20(6):729-739. PubMed ID: 30915884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
